Last reviewed · How we verify
Compound Clobetasol Propionate Ointment
Clobetasol propionate is a potent topical corticosteroid that suppresses inflammatory and immune responses in the skin by binding to glucocorticoid receptors.
Clobetasol propionate is a potent topical corticosteroid that suppresses inflammatory and immune responses in the skin by binding to glucocorticoid receptors. Used for Inflammatory and pruritic dermatoses responsive to topical corticosteroids (e.g., psoriasis, lichen planus, severe eczema), Severe dermatitis and other inflammatory skin conditions.
At a glance
| Generic name | Compound Clobetasol Propionate Ointment |
|---|---|
| Sponsor | First Hospital of China Medical University |
| Drug class | Topical corticosteroid (Class I/super-potent) |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Mechanism of action
Clobetasol propionate is a Class I (super-potent) corticosteroid that works by activating intracellular glucocorticoid receptors, leading to decreased production of inflammatory mediators, reduced immune cell infiltration, and suppression of local inflammatory responses. It is applied topically to affected skin areas where it reduces erythema, pruritus, and other signs of dermatological inflammation.
Approved indications
- Inflammatory and pruritic dermatoses responsive to topical corticosteroids (e.g., psoriasis, lichen planus, severe eczema)
- Severe dermatitis and other inflammatory skin conditions
Common side effects
- Skin atrophy
- Striae
- Telangiectasia
- Local irritation or burning
- Systemic corticosteroid absorption (with prolonged use or occlusion)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: